
1. n engl j med. 2010 oct 14;363(16):1499-509. doi: 10.1056/nejmoa0906626.

antiretroviral therapies women single-dose nevirapine exposure.

lockman s(1), hughes md, mcintyre j, zheng y, chipato t, conradie f, sawe f,
asmelash a, hosseinipour mc, mohapi l, stringer e, mngqibisa r, siika a, atwine
d, hakim j, shaffer d, kanyama c, wools-kaloustian k, salata ra, hogg e,
alston-smith b, walawander a, purcelle-smith e, eshleman s, rooney j, rahim s,
mellors jw, schooley rt, currier js; octane a5208 study team.

collaborators: zwickl b, mutuluuza ck, kaseba c, maponga cc, watts h, kuritzkes
d, campbell tb, kidd-freeman l, carten m, hitti j, marovich m, mugyenyi pn,
rwambuya s, sanne im, putnam b, marcus c, wester c, difrancesco r, halvas e,
beddison a, lehrman s, aweeka f, dong b, ziba pn, saag ms, holmes wc, hammer sm, 
dangaiso e, rassool ms, tsotsotetsi j, potani c, mwausegha r, laher f, hen-boisen
r, kirwa k, nzioka a, chibowa m, stringer j, sebina k, mburu k, kakhu t, moorad
b, kityo c, rwambuya s, amod f, lalloo u, pillay s, sun x, nair a, smith lm,
tutko j, lee c, purdue l, ferguson e, martinez a, delph y, gettinger n, berman l,
boone l, adedeji b.

author information: 
(1)brigham women's hospital, boston, ma, usa. slockman@hsph.harvard.edu

comment in
    n engl j med. 2010 oct 14;363(16):1570-2.

background: peripartum administration single-dose nevirapine reduces
mother-to-child transmission human immunodeficiency virus type 1 (hiv-1) but
selects nevirapine-resistant virus.
methods: seven african countries, women infected hiv-1 whose cd4+ t-cell 
counts 200 per cubic millimeter either taken
single-dose nevirapine least 6 months enrollment randomly assigned
to receive antiretroviral therapy tenofovir–emtricitabine plus nevirapine or
tenofovir-emtricitabine plus lopinavir boosted low dose ritonavir. the
primary end point time confirmed virologic failure death.
results: total 241 women exposed single-dose nevirapine
began study treatments (121 received nevirapine 120 received
ritonavir-boosted lopinavir). significantly women nevirapine group
reached primary end point ritonavir-boosted lopinavir group (26% 
vs. 8%) (adjusted p=0.001). virologic failure occurred 37 (28 the
nevirapine group 9 ritonavir-boosted lopinavir group), 5 died
without prior virologic failure (4 nevirapine group 1 the
ritonavir-boosted lopinavir group). group differences appeared decrease as
the interval single-dose nevirapine exposure start of
antiretroviral therapy increased. retrospective bulk sequencing baseline
plasma samples showed nevirapine resistance 33 239 women tested (14%).
among 500 women without prior exposure single-dose nevirapine, 34 249 in
the nevirapine group (14%) 36 251 ritonavir-boosted lopinavir group
(14%) virologic failure died.
conclusions: women prior exposure peripartum single-dose nevirapine
(but without prior exposure), ritonavir-boosted lopinavir plus
tenofovir–emtricitabine superior nevirapine plus tenofovir–emtricitabine
for initial antiretroviral therapy. (funded national institute allergy 
and infectious diseases national research center; clinicaltrials.gov
number, nct00089505.).

doi: 10.1056/nejmoa0906626 
pmcid: pmc2994321
pmid: 20942666  [indexed medline]

